Safran anticipates further sales and profit growth next year and said it intends to return about 70% of its cash generation to shareholders from 2025 to 2028.
Related Posts
Regeneron, Sanofi Get FDA OK for Dupixent to Treat COPD
Regeneron Pharmaceuticals and Sanofi have won FDA expanded approval of their blockbuster anti-inflammatory drug Dupixent in chronic obstructive pulmonary disease.
ASML Orders Boosted by AI Chip Boom
ASML booked orders ahead of market forecasts as chip makers rush to get their hands on key production equipment to meet booming AI demand, but […]
How the Justice Department Is Changing Its Tactics on Cybercrime
The assistant U.S. attorney general for national security outlines where the biggest threats are coming from—and what kinds of attacks are most worrisome